Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| ChiRhoClin, Inc. | INDUSTRY |
Not provided
Not provided
Not provided
The purpose of this study is to collect pancreas fluid from the duodenum using the endoscopic pancreas function collection method in healthy participants after pancreatic stimulation with human secretin.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Healthy Participants | Experimental | Healthy participants without pancreatic disease who are undergoing an endoscopic ultrasound for a non-pancreatic indication. Participants will be given a standard dose of intravenous human secretin (0.2 mcg/kg) during the endoscopic ultrasound. During this time, pancreatic fluid will be collected at 5 minutes, 10 minutes, 15 minutes, and 20 minutes after secretin administration. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Secretin (human synthetic) - ChiRhoClin | Drug | During endoscopic ultrasound (EUS), a dose of intravenous secretin (0.2 µg/kg) will be administered over the course of 1 minute to stimulate pancreatic ductal cells to secrete pancreas fluid. Duodenal fluid will be aspirated through the echoendoscope in 5 minute increments (5, 10, 15, and 20 minutes) after the secretin has been administered |
| Measure | Description | Time Frame |
|---|---|---|
| Pancreatic Fluid Bicarbonate Composition | A primary outcome will be the bicarbonate level (milliequivalent per liter) in the pancreatic fluid collected. | 5, 10, 15, and 20-minutes post-secretin administration |
| Pancreatic Fluid Sodium Composition | A primary outcome will be the sodium level (milliequivalent per liter) in the pancreatic fluid collected. | 5, 10, 15, and 20-minutes post-secretin administration |
| Pancreatic Fluid Potassium Composition | A primary outcome will be the potassium level (milliequivalent per liter) in the pancreatic fluid collected. | 5, 10, 15, and 20-minutes post-secretin administration |
| Pancreatic Fluid Chloride Composition | A primary outcome will be the chloride level (milliequivalent per liter) in the pancreatic fluid collected. | 5, 10, 15, and 20-minutes post-secretin administration |
Not provided
Not provided
Inclusion Criteria
Exclusion Criteria
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Liz Lemke | Contact | 507-266-3317 | Lemke.Elizabeth@mayo.edu | |
| Samuel Han, MD | Contact | han.samuel@mayo.edu |
| Name | Affiliation | Role |
|---|---|---|
| Samuel Han, MD | Mayo Clinic | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Mayo Clinic in Rochester | Recruiting | Rochester | Minnesota | 55905 | United States |
Not provided
| Label | URL |
|---|---|
| Mayo Clinic Clinical Trials | View source |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D010188 | Exocrine Pancreatic Insufficiency |
| D050500 | Pancreatitis, Chronic |
| ID | Term |
|---|---|
| D010182 | Pancreatic Diseases |
| D004066 | Digestive System Diseases |
| D010195 | Pancreatitis |
| D002908 | Chronic Disease |
Not provided
Not provided
| ID | Term |
|---|---|
| D012633 | Secretin |
| ID | Term |
|---|---|
| D005768 | Gastrointestinal Hormones |
| D006728 | Hormones |
| D006730 | Hormones, Hormone Substitutes, and Hormone Antagonists |
| D036361 | Peptide Hormones |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
|
| D020969 |
| Disease Attributes |
| D010335 | Pathologic Processes |
| D013568 | Pathological Conditions, Signs and Symptoms |
| D009479 | Neuropeptides |
| D010455 | Peptides |
| D000602 | Amino Acids, Peptides, and Proteins |
| D009419 | Nerve Tissue Proteins |
| D011506 | Proteins |